108-71-4

Basic information

• Product Name: toluene-3,5-diamine
• Synonyms: toluene-3,5-diamine;EINECS 203-609-1;1,3-diamino-5-methylbenzene;5-methyl-3-benzenediamine;toluene, 3,5-diamino-toluene;5-Methyl-1,3-benzenediamine;5-Methyl-m-phenylenediamine
• CAS NO: 108-71-4
• Molecular Formula: C₇H₁₀N₂
• Molecular Weight: 122.1677
• EINECS: 203-609-1
• Mol File: 108-71-4.mol

Chemical Properties

• Melting Point: 98.1°C
• Boiling Point: 217.6°C (rough estimate)
• Flash Point: 152.9 °C
• Appearance: /
• Density: 1.0343 (rough estimate)
• Vapor Pressure: 0.00306mmHg at 25°C
• Refractive Index: 1.6100 (estimate)
• CAS DataBase Reference: toluene-3,5-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: toluene-3,5-diamine(108-71-4)
• EPA Substance Registry System: toluene-3,5-diamine(108-71-4)

Safety Data

• Hazardous Substances Data: 108-71-4(Hazardous Substances Data)

Usage

Uses

Used in Hair Dye and Coloring Products Industry:
Toluene-3,5-diamine is used as a key component in the formulation of hair dyes and coloring products for its ability to impart color to hair. It is valued for its effectiveness in creating a wide range of shades and tones, enhancing the aesthetic appeal of hair care products.
Used in Regulatory Compliance:
Toluene-3,5-diamine is used as a subject of regulatory oversight by health and safety agencies to ensure that its production and use adhere to strict safety standards. This is crucial for minimizing potential risks to human health and the environment, reflecting the importance of responsible chemical management in various industries.

InChI:InChI=1/C7H10N2/c1-5-2-6(8)4-7(9)3-5/h2-4H,8-9H2,1H3

Upstream product

• 618-85-9 3,5-dinitrotoluene 
• 7647-01-0 hydrogenchloride 
• 857001-30-0 2,4-dibromo-3,5-dinitro-toluene 
• 106-49-0 p-toluidine 
• 618-61-1 3-methyl-5-nitro-aniline 
• 103-89-9 4-Methylacetanilide 
• 49804-47-9 N-(4-methyl-2,6-dinitrophenyl)acetamide 
• 1611-92-3 3,5-dibromotoluene 
• 99-99-0 1-methyl-4-nitrobenzene 
• 121-14-2 2,4-dinitrotoluene 
• 606-20-2 2,6-dinitrotoluene 
• 602-01-7 1-methyl-2,3-dinitrobenzene 
• 619-15-8 2,5-dinitrotoluene 
• 60546-37-4 4-methyl-2,6-dinitro-phenetole 

Downstream Products

• 91-08-7 2,6-Toluene diisocyanate 
• 14219-05-7 toluene-3,5-diisocyanate 
• 584-84-9 2,4-Toluene diisocyanate 
• 614-90-4 toluene-2,5-diisocyanate 
• 40553-77-3 2,8-Diamino-1,9-dimethylacridin 
• 14815-16-8 Di-trifluoracetyl-diaminotoluol-(3,5) 

Relevant articles and documents

Immobilized silver nanoparticles on silica gel as an efficient catalyst in nitroarene reduction

Nanoparticles have properties that can be fine-tuned by their size as well as shape. Hence, there is significant current interest in preparing nano-materials of small size dispersity and to arrange them in close-packed aggregates. This letter describes a way of synthesising silver nanoparticles and their protection to aggregate by silica gel. The combination of catalytic quantities of immobilized silver nanoparticles with reductive ability of NaBH4 efficiently reduces aromatic nitroarenes to the corresponding amines in aqueous medium. Noteworthy is that highly chemoselective reactions were achieved in the presence of other functional groups such as halogen and carboxylic acid groups. The silver particles immobilized on silica gel are stable in the presence of oxygen for several months.

Preparation process of low-cost and environment-friendly bisphenol S

The invention discloses a preparation process of bisphenol S with low cost and environmental protection. When the corrosion-resistant paint is sprayed into the interior of the reaction kettle, N atoms and O atoms of the reinforcing filler can interact with the metal ions to form a chelate. The acid resistance of the reaction kettle is higher, and the preparation cost is further reduced.

DNA interaction of bromomethyl-substituted acridines

A series of acridines with bifunctional substituents was synthesized with the dual properties of DNA alkylation and intercalation. 4,5-Bis(bromomethyl)acridine (1) was previously reported to crosslink and intercalate with DNA. In this study, 1,8-bis(bromomethyl)acridine (2) and 2,7-bis(bromomethyl)acridine (3), monofunctional 2-(bromomethyl)-7-methylacridine (4) and 2,7-dimethylacridine (5) were synthesized, and their crosslinking and intercalative activities were investigated to assess the reactivity of bromomethyl acridines with DNA. Interstrand crosslinking activity was similar among the three bis(bromomethyl)acridines. The acridines exhibited intercalation activity for calf thymus DNA as follows: 3 > 4 > 2 = 1 5. Intracellular DNA-crosslinking and DNA-intercalating activities were evaluated using the Ames assay. 4 was mutagenic in Salmonella typhimurium TA100 and TA98, indicating that the bromomethyl group alkylated DNA bases. All three bis(bromomethyl)acridines were mutagenic in S. typhimurium TA92 and TA94, which can detect intracellular crosslinking DNA damage, whereas 5 was not mutagenic in these strains. The results showed that the bis(bromomethyl)acridines crosslinked DNA and intercalated between DNA bases, and 3 exhibited the highest crosslinking and intercalating activity.

Diamination of phenylene dihalides catalyzed by a dicopper complex

Diamination of phenylene dihalides with aqueous ammonia to give the corresponding phenylenediamines can be achieved by using a dicopper complex [Cu2(bpnp)(OH)(CF3COO)3] (1) (bpnp = 2,7-bis(pyridine-2-yl)-l,8-naphthyridine) as the catalyst in the presence of Bu4NBr and Cs2CO3 in high yields. In addition, 1,3,5-tribromobenzene was converted into benzenetriamine quantitatively under the same conditions. This method offers a new opportunity, particularly simplifying steps and increasing yields, for the preparation of aryl diamines.

Process for the production of the toluene diisocyanate

The invention relates to a process for the production of toluene diisocyanate, in which the crude toluenediamine obtained from the hydrogenation is purified and then phosgenated. The purification step reduces the total amount of cyclic ketones to less than 0.1 % by weight, based on 100% by weight of the toluenediamine.

Process for separating mixtures of materials having different boiling points

A mixture of materials having different boiling points is separated into fractions having different boiling points. The separated fraction containing the desired product is stripped using the vapors of a lower boiling fraction. The process of the present invention is particularly useful for recovering a desired isomer or isomer mixture from a technical mixture obtained during production of an aromatic amine such as toluenediamine. Little or no unwanted isomer or by-product is present in the isomer or isomer mixture product of this process.

2-IMIDAZOLINE, 2-OXAZOLINE, 2-THIAZOLINE, AND 4-IMIDAZOLE DERIVATIVES OF METHYLPHENYL, METHOXYPHENYL, AND AMINOPHENYL ALKYLSULFONAMIDES AND UREAS AND THEIR USE

The present invention concerns novel compounds represented by the Formula: STR1 wherein: A is R 1 q (R 3 R 60 N). sub.m (Z)(NR 2) n ; m and q are each 0 or 1, with the proviso that when q is 1, m is 0 and when q is 0, m is 1; Z is C=O or SO 2 ; n is 1 with the proviso that, when Z is C=O, m is 1; X is--NH--,--CH 2--, or--OCH 2--; Y is 2-imidazoline, 2-oxazoline, 2-thiazoline, or 4-imidazole; R 1 is H, lower alkyl, or phenyl, with the proviso that, when R 1 is H, m is 1; R 2, R 3, R 60 are each independently H, lower alkyl, or phenyl; R 4, R 5, R. sup.6, and R 7 are each independently hydrogen, lower alkyl,--CF. sub.3, lower alkoxy, halogen, phenyl, lower alkeny, hydroxyl, lower alkylsulfonamido, or lower cycloalkyl, wherein R. sup.2 and R 7 optionally may be taken together to form alkylene or alkenylene of 2 to 3 atoms in an unsubstituted or optionally substituted 5-or 6-membered ring, wherein the optional substituents on the ring are halo, lower alkyl, or--CN, with the proviso that, when R 7 is hydroxyl or lower alkylsulfonamido, then X is not--NH--when Y is 2-imidazoline. The compounds include pharmaceutically acceptable salts of the above. In the above formula A may be, for example, (R 1 SO 2 NR 2--), (R. sup.3 R 60 NSO 2 NR 2--), or (R 3 R 60 NCONR 2--). The invention also includes the use of the above compounds, and compositions containing them, as alpha 1A/1L agonists in the treatment of various disease states such as urinary incontinence, nasal congestion, priapism, depression, anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and cognition, and eating disorders such as obesity, bulimia, and anorexia.

Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists

The present invention concerns novel compounds represented by the Formula:*(formula 02)* wherein: A is R1q(R3R60N)m(Z)(NR2)n; m and q are each 0 or 1, with the proviso that when q is 1, m is 0 and when q is 0, m is 1; Z is C=O or SO 2; n is 1 with the proviso that, when Z is C=O, m is 1; X is -NH-, -CH2-, or -OCH2-; Y is 2-imidazoline, 2-oxazoline, 2-thiazoline, or 4-imidazole; R 1 is H, lower alkyl, or phenyl, with the proviso that, when R1 is H, m is 1; R2, R3, R60 are each independently H, lower alkyl, or phenyl; R4, R5, R6, and R7 are each independently hydrogen, lower alkyl, - CF 3, lower alkoxy, halogen, phenyl, lower alkeny, hydroxyl, lower alkylsulfonamido, or lower cycloalkyl, wherein R2 and R7 optionally may be taken together to form alkylene or alkenylene of 2 to 3 atoms in an unsubstituted or optionally substituted 5-or 6-membered ring, wherein the optional substituents on the ring are halo, lower alkyl, or -CN,with the proviso that, when R7 is hydroxyl or lower alkylsulfonamido, then X is not -NH- when Y is 2-imidazoline. The compounds include pharmaceutically acceptable salts of the above. In the above formula A may be, for example, (R1SO2NR2-), (R3R60NSO2NR2-), or (R3R60NCONR2-). The invention also includes the use of the above compounds, and compositions containing them, as alpha 1A/1L agonists in the treatment of various disease states such as urinary incontinence, nasal congestion, priapism, depression, anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and cognition, and eating disorders such as obesity, bulimia, and anorexia.